Patents by Inventor Jan Rothenburger
Jan Rothenburger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180344717Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.Type: ApplicationFiled: July 26, 2018Publication date: December 6, 2018Inventors: Federico GAETA, Klaus GERDES, Stefan WELZIG, Beate KAELZ, Jan ROTHENBURGER, Jozsef GUNGL
-
Publication number: 20170239228Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.Type: ApplicationFiled: May 8, 2017Publication date: August 24, 2017Inventors: Federico GAETA, Klaus GERDES, Stefan WELZIG, Beate KAELZ, Jan ROTHENBURGER, Jozsef GUNGL
-
Patent number: 9675598Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.Type: GrantFiled: August 1, 2016Date of Patent: June 13, 2017Assignee: Sanochemia Pharmazeutika AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Patent number: 9662317Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.Type: GrantFiled: March 11, 2016Date of Patent: May 30, 2017Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Publication number: 20160367540Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.Type: ApplicationFiled: August 1, 2016Publication date: December 22, 2016Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Publication number: 20160220549Abstract: The present disclosure relates to methods of administering tolperisone to subjects in need thereof. In certain aspects, the present disclosure relates to methods of administering tolperisone to subjects in need thereof, said methods limiting the exposure of the subject to 4-MMPPO.Type: ApplicationFiled: March 11, 2016Publication date: August 4, 2016Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Katz, Jan Rothenburger, Jozsef Gungl
-
Patent number: 9315480Abstract: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.Type: GrantFiled: April 24, 2008Date of Patent: April 19, 2016Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Kalz, Jan Rothenburger, József Gungl
-
Patent number: 8372979Abstract: The invention relates to a method for producing highly pure 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e.Type: GrantFiled: April 24, 2008Date of Patent: February 12, 2013Assignee: SANOCHEMIA Pharmazeutika AGInventors: Stefan Welzig, Jan Rothenburger, Beate Kälz, József Gungl, Klaus Gerdes, Federico Gaeta
-
Patent number: 8212029Abstract: A process for the production of extremely pure galanthamine and galanthamine derivatives is provided. Racemic bromine narwedine is debrominated under palladium catalysis. The reaction mixture is then worked-up in the presence of oxygen or peroxides so that the palladium catalyst is converted into an insoluble form that can be easily separated. Further reaction is carried out by reduction of enantiomerically pure narwedine to form enantiomerically pure galanthamine, which is then alkylated or dealkylated, so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved. The pure galanthamine can then be directly used as a pharmaceutical raw material.Type: GrantFiled: February 14, 2008Date of Patent: July 3, 2012Assignee: Sanochemia Pharmazeutika AGInventors: Stefan Welzig, Anton Gerdenitsch, Jan Rothenburger, Susanne Kolar, Alexandra Scherleithner
-
Publication number: 20100324090Abstract: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.Type: ApplicationFiled: April 24, 2008Publication date: December 23, 2010Inventors: Federico Gaeta, Klaus Gerdes, Stefan Welzig, Beate Kätz, Jan Rothenburger, József Gungl
-
Publication number: 20100249423Abstract: A GRDDS (Gastro Retentive Drug Delivery System) containing tolperisone and having a 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) fraction of less than 1.5 ppm for the extended release of the active substance tolperisone while avoiding the formation of 4-MMPPO in the gastrointestinal tract.Type: ApplicationFiled: February 19, 2010Publication date: September 30, 2010Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Jan Rothenburger, Beate Kälz, József Gungl, Klaus Gerdes
-
Publication number: 20100150995Abstract: The invention relates to a method for producing highly pure 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e.Type: ApplicationFiled: April 24, 2008Publication date: June 17, 2010Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Jan Rothenburger, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Federico Gaeta
-
Publication number: 20100105895Abstract: A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, whereby a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. The working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides, is essential to the process, so that the palladium catalyst is converted into an insoluble form, a form that can be easily separated. The further reaction is carried out by reduction of enantiomerically pure narwedine to form enantiomerically pure galanthamine, whereby it is then alkylated or dealkylated, so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that the direct use as a pharmaceutical raw material is made possible.Type: ApplicationFiled: February 14, 2008Publication date: April 29, 2010Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Anton Gerdenitsch, Jan Rothenburger, Susanne Kolar, Alexandra Scherleithner
-
Publication number: 20090326219Abstract: A process for the production of extremely pure galanthamine or extremely pure galanthamine derivatives, a start is made from racemic bromine narwedine, which is debrominated under palladium catalysis. In this case, the working-up of the reaction mixture, which is carried out in the presence of oxygen or peroxides so that the palladium catalyst in an insoluble form is converted into an easily separable form, is essential. The further reaction is carried out by reduction of enantiomer-pure narwedine to form enantiomer-pure galanthamine, whereby it is then alkylated or dealkylated so that a corresponding substitution on the ring-nitrogen atom is achieved. By further purification, such as recrystallization, residual portions of palladium of below 5 ppm are achieved, so that direct use as a pharmaceutical raw material is made possible.Type: ApplicationFiled: June 26, 2009Publication date: December 31, 2009Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Klaus GERDES, József GUNGL, Beate KÄLZ, Jan ROTHENBURGER, Stefan WELZIG
-
Publication number: 20090253743Abstract: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.Type: ApplicationFiled: November 26, 2008Publication date: October 8, 2009Applicants: Avigen, Inc., Sanochemia Pharmazeutika, AGInventors: Federico Gaeta, Stefan Welzig, Jan Rothenburger, Beate Kalz, Jozsef Gungl, Klaus Gerdes
-
Publication number: 20080188522Abstract: The invention relates to a method for producing an acid addition salt of 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) with a pharmaceutically acceptable acid, of the formula (I). According to the invention, 4-methylpropiophenone is reacted with piperidine hydrochloride and 1,2-dioxolane in the presence of an acid serving as a catalyst, and the tolperisone obtained in the form of an acid addition salt is separated by filtering after the reaction mixture has cooled down.Type: ApplicationFiled: April 4, 2008Publication date: August 7, 2008Applicant: SANOCHEMIA PHARMAZEUTIKA AGInventors: Laszlo Czollner, Beate Kalz, Jan Rothenburger, Stefan Welzig
-
Patent number: 7385060Abstract: The invention relates to a method for producing an addition salt of 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) with a pharmaceutically acceptable acid, of formula (I).Type: GrantFiled: March 31, 2003Date of Patent: June 10, 2008Assignee: Sanochemia Pharmazeutika AGInventors: Laszlo Czollner, Beate Kälz, Jan Rothenburger, Stefan Welzig
-
Publication number: 20060041141Abstract: The invention relates to a method for producing an addition salt of 2,4?-dimethyl-3-piperidino-propiophenone (tolperisone) with a pharmaceutically acceptable acid, of formula (I). According to the invention, 4-methylpropiophenone is reacted with piperidine hydrochloride and 1,2-dioxolane in the presence of an acid serving as a catalyst, and the tolperisone obtained in the form of an acid addition salt is separated by filtering after the reaction mixture has cooled down.Type: ApplicationFiled: March 31, 2003Publication date: February 23, 2006Inventors: Laszlo Czollner, Beate Kalz, Jan Rothenburger, Stefan Welzig